- Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)
July 30 2009 - 7:16AM
Edgar (US Regulatory)
Issuer Free Writing Prospectus Dated July 30, 2009
Filed Pursuant to Rule 433
Relating to
Registration Statement No. 333-159078
Endologix, Inc.
3,900,000 shares
This free writing prospectus relates only to the securities described in, and should be read together
with, the prospectus dated June 1, 2009 (the Prospectus) included in Endologix, Inc.s Registration Statement on Form S-3 (Registration No. 333-159078) relating to these securities. The following information supplements
and updates the information contained in the Prospectus.
Nasdaq Global Market symbol:
|
ELGX
|
Shares offered by the issuer:
|
3,900,000 shares
|
Price to the public:
|
$4.10 per share
|
Net proceeds to the issuer:
|
$14,715,000
|
Dilution:
|
As of June 30, 2009, Endologix had a historical net tangible book value of common stock of approximately $0.33 per share. Based on the public offering price of $4.10 per share, if you purchase shares of
common stock in this offering, you will incur an immediate dilution in net tangible book value of approximately $3.49 per share, and as a result of the offering, existing stockholders of Endologix will experience an immediate increase in net
tangible book value of approximately $0.28 per share.
|
Trade date:
|
July 30, 2009
|
Closing date:
|
August 4, 2009
|
Underwriter:
|
Piper Jaffray & Co.
|
Endologix filed a registration statement (including a prospectus)
with the Securities and Exchange Commission (the SEC) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents Endologix has filed with the
SEC for more complete information about Endologix and this offering. You may obtain these documents for free by visiting EDGAR or the SEC website at www.sec.gov. Alternatively, a written prospectus and accompanying prospectus supplement related to
the
offering may be obtained from Piper Jaffray & Co. at 800 Nicollet Mall, Minneapolis, MN 55402, Attention: Equity Capital Markets, or by telephone at
(800) 747-3924.
ANY DISCLAIMER OR OTHER NOTICES THAT MAY APPEAR AFTER THIS MESSAGE ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE
DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From May 2024 to Jun 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2023 to Jun 2024